GLP-1R agonist withdrawal effect on weight loss and cardiovascular risks remains unmet need: GlobalData Read more
Eli Lilly’s Mounjaro to become leading GLP-1 therapy for type 2 diabetes in NHS in UK: GlobalData Read more
US FDA approves Lilly and Incyte’s Olumiant for treating certain hospitalised patients with COVID-19 Read more